Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CIDEA
REST API REST API
Homo sapiens
CIDEA is differentially expressed in 130 experiments: 96 organism parts: hypothalamus, adipose tissue, ... (94 more);, 91 disease states: normal, healthy, ... (89 more);, 30 cell types 65 cell lines 13 compound treatments and 55 other conditions.
Synonyms CIDE-A
Orthologs CIDEA (Gallus gallus)   Cidea (Mus musculus)   CIDEA (Danio rerio)   Cidea (Rattus norvegicus)   cidea (Xenopus laevis)   ENSBTAG00000046547 (Bos taurus)   CIDEA (Canis familiaris)   A4FUX1_BOVIN (Bos taurus)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, cytoplasm, DNA damage response, signal transduction resulting in induction of apoptosis, intracellular, negative regulation of apoptosis, lipid particle, negative regulation of transforming growth factor beta receptor signaling pathway, mitochondrial envelope, lipid metabolic process, nucleus, cell death, lipid storage, protein homodimerization activity, DNA fragmentation involved in apoptotic nuclear change, mitochondrion, positive regulation of sequestering of triglyceride, negative regulation of lipid catabolic process, negative regulation of cytokine secretion, temperature homeostasis, negative regulation of tumor necrosis factor production
InterPro Term CAD
UniProt Accession B3KVA2, O60543, E5RJ03
Search EB-eye ENSG00000176194
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (14 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-22639, E-GEOD-2450, ... (14 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
NCIH661
1
E-MTAB-37
CWR22Rv1
1
E-GEOD-17482
DU145
1
1
E-GEOD-17482
A673
1
1
E-MTAB-62
RKOE6
1
E-MTAB-37
59 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (20 experiments)

Factor Value U/D Experiments
CD4+ T cell
6
2
E-MTAB-24, E-MTAB-25
epithelial cell
2
E-GEOD-10797, E-MEXP-2034
PBMCs
1
E-GEOD-20677
primary fibroblast
1
E-MEXP-66
immortalized cell culture
1
E-GEOD-14990
CD56+ NK cells
1
1
E-AFMX-5
24 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2508, E-GEOD-1577, E-GEOD-5563, E-GEOD-2549, ... (33 experiments)

Factor Value U/D Experiments
lipoma
2
E-MTAB-62, E-GEOD-6481
astrocytoma
1
E-MTAB-37
HCL (Hairy Cell Leukemia)
1
E-GEOD-16455
myocardial infarction
1
E-MTAB-62
B-precursor acute lymphoblastic leukemia
1
E-GEOD-1577
sarcoma
1
E-GEOD-2719
85 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-3284, E-GEOD-7216, E-TABM-127, E-GEOD-5824, ... (8 experiments)

Factor Value U/D Experiments
estradiol
1
E-GEOD-20081
cigarette smoke
1
1
E-TABM-127
unknown
1
E-GEOD-7307
dimethyl sulfoxide
1
E-GEOD-5824
rapamycin
1
E-GEOD-5824
bacterial endotoxin
1
1
E-GEOD-3284
7 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
84
1
1
E-GEOD-21653


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-GEOD-4667, E-MEXP-2283

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-21138

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-3494, E-TABM-321

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-GEOD-22278, E-GEOD-9764, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20559, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-5764, E-GEOD-974, E-MEXP-2069, E-GEOD-19330, ... (20 experiments)

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-1343

RNAi
studied in E-GEOD-3697

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.506 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM